An accomplished medical professional, Nadia Al-Aydi serves as a senior brand manager with Votrient US. To augment this role, which she began in 2019, Nadia Al-Aydi is a member of the American Society of Clinical Oncology (ASCO), which aims to improve cancer care across the country.
The organization has commended the U.S. Food and Drug Administration (FDA) for encouraging the inclusion of older cancer patients in clinical trials. The response comes after the FDA released draft guidance on the topic, which was developed by Richard Pazdur, MD, the director of the FDA Oncology Center of Excellence.
Speaking about the guidance, ASCO President Howard A. Burris III, MD, highlights that evidence-based cancer research focused on older patients is scarce, with this largely the result of their exclusion from clinical trials. He notes that, in turn, oncologists have less reliable evidence to draw on to treat their patients effectively.
As such, he has commended the FDA for the draft guidance, suggesting that it is a much-needed signal to medical research professionals to be more inclusive when conducting trials.
